Cyclosporine versus everolimus: effects on the glomerulus. (24th June 2013)

• Record Type: Journal Article
• Authors: Baas, Marije C.; Kers, Jesper; Florquin, Sandrine; de, Johan W.; Homan van der Heide, Jaap J.; van den, Marius A.; ten Berge, Ineke J. M.; Bemelman, Frederike J.
• Is Part Of: Clinical transplantation. Volume 27:Number 4(2013:Jul./Aug.)
• Page Start: 535
• Page End: 540
• Publication Date: 2013-06-24
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.12144
• Languages: English
• ISSNs: 0902-0063

Abstract

<abstract abstract-type="main" id="ctr12144-abs-0001"> <title>Abstract</title> <p>Inhibitors of the mammalian target of rapamycin (mTOR) have been associated with proteinuria. We studied the development of proteinuria in renal transplant recipients (RTR) treated with the mTOR inhibitor everolimus in comparison with a calcineurin inhibitor. We related the presence of proteinuria to histopathological glomerular findings in two‐yr protocol biopsies. In a single‐center study, nested in a multicenter randomized controlled trial, we determined eGFR, proteinuria, and renal biopsy data (light‐ and electron microscopy) of RTR receiving prednisolone/everolimus (P/EVL) (n = 16) in comparison with patients treated with prednisolone/cyclosporine A (P/CsA) (n = 7). All patients had been on the above‐described maintenance immunosuppression for 18 months. Renal function at two yr after transplantation did not differ between patients receiving P/EVL or P/CsA (eGFR 45.5 vs. 45.7 mL/min/1.73 m²). Proteinuria was slightly increased in P/EVL vs. P/CsA group (0.29 vs. 0.14 g/24 h, p = 0.06). There were no differences in light‐ or electron microscopic findings. We could not demonstrate increased podocyte effacement or changes in glomerular basement membrane (GBM) thickness in P/EVL‐treated patients. In conclusion, long‐term treatment with everolimus leaves the GBM and podocytes unaffected.</p> </abstract>